However, knockdown of KDM2B sensitized these cells to ABT and TRAIL combination (Supplementary Figure 7), and KDM2B overexpression was able to confer GBM cells more resistant to ABT and TRAIL combination (Supplementary Figure 8). The gene discussed is TNFSF10; the disease is glioblastoma.